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Take home message: 
In this first study of standardised multi-site flow cytometry in acutely unwell patients 
with suspected infections attending emergency departments, we explored which of 
47 leukocyte biomarkers reliably discriminates which patients develop sepsis over 
the next 3 days, defined according to the Sepsis-3 sepsis criteria.  
After highlighting the importance of test reliability (14 biomarkers lacked 
measurement reliability) and comparator cohorts (a further 17 biomarkers did not 
discriminate acutely unwell patients with suspected infection from patients with 
established sepsis-related critical illness and/or non-infective acute illness), we found 
that none of the remaining 16 biomarkers had clinically relevant predictive ability for 
subsequent sepsis or other important clinical outcomes. However, markers of early 
immune suppression (neutrophil and monocyte CD274 and CD279; monocyte HLA-
DR) had the strongest associations with clinical outcomes. The optimum biomarker 
combination associated with clinical deterioration to sepsis was increased neutrophil 
CD24 and CD279 and reduced monocyte HLA-DR expression.  
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Abstract 
Purpose: 
Reliable biomarkers for predicting subsequent sepsis among patients with suspected 
acute infection are lacking. In patients presenting to emergency departments (EDs) 
with suspected acute infection, we aimed to evaluate the reliability and discriminant 
ability of 47 leukocyte biomarkers as predictors of sepsis (Sequential Organ Failure 
Assessment score ≥2 at 24 hours and/or 72 hours following ED presentation). 
Methods: 
In a multi-centre cohort study in four EDs and intensive care units (ICUs), we 
standardised flow-cytometric leukocyte biomarker measurement, and compared 
patients with suspected acute infection (cohort-1), with two comparator cohorts: ICU 
patients with established sepsis (cohort-2); and ED patients without infection or 
systemic inflammation but requiring hospitalization (cohort-3). 
Results: 
Between January 2014 and February 2016, we recruited 272, 59 and 75 patients to 
cohorts 1, 2, and 3 respectively. Of 47 leukocyte biomarkers, 14 were non-reliable, 
and 17 did not discriminate between the three cohorts. Discriminant analyses for 
predicting sepsis within cohort-1 were undertaken for eight neutrophil (cluster of 
differentiation antigens (CD) CD15;CD24;CD35;CD64;CD312;CD11b;CD274; 
CD279), seven monocyte (CD35;CD64;CD312;CD11b;HLA-DR;CD274;CD279) and 
a CD8 T-lymphocyte biomarker (CD279). Individually, only higher neutrophil CD279 
(OR 1.78 (95%CI:1.23-2.57);P=0.002), higher monocyte CD279 (1.32 (1.03-
1.70);P=0.03), and lower monocyte HLA-DR (0.73 (0.55-0.97);P=0.03) expression 
were associated with subsequent sepsis. With logistic regression the optimum 
biomarker combination was increased neutrophil CD24 and neutrophil CD279, and 
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reduced monocyte HLA-DR expression, but no combination had clinically relevant 
predictive validity.  
Conclusions:  
From a large panel of leukocyte biomarkers, immunosuppression biomarkers were 
associated with subsequent sepsis in ED patients with suspected acute infection.  
Clinical trial registration: NCT02188992 
Key words 
Sepsis; infection; mortality; cohort study; biomarker, risk prediction 
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Introduction 
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response 
to infection[1]. Host immune responses result from leukocytes sensing pathogen- 
and tissue damage-associated danger signals[2, 3]. Sepsis-related immune 
responses involve both humoral and leukocyte components of the innate and 
adaptive immune systems, with excessive inflammation and immunosuppression 
occurring simultaneously in most patients[2, 3]. These are thought to influence the 
resulting clinical phenotypes and outcomes[3, 4]. 
Leukocyte responses in sepsis measured using flow cytometry detects leukocyte 
biomarkers, including surface markers and/or leukocyte subsets[5]. Previous flow 
cytometry-based leukocyte biomarker studies in sepsis were mostly small single 
centre studies in patients with sepsis, typically focusing on a limited panel of 
biomarkers. These studies rarely evaluated biomarker reliability and reproducibility, 
which is methodologically and clinically relevant as it influences diagnostic validity[6]. 
In addition, few studies used robust unbiased designs to assess predictive ability for 
clinically relevant outcomes in unselected populations with suspected infections prior 
to developing organ dysfunction and established sepsis. 
We hypothesized that among patients with clinically suspected acute infection but 
without established sepsis, leukocyte biomarkers would identify patients who 
subsequently deteriorate clinically and develop sepsis, when measured within a few 
hours of presentation to the emergency department (ED). Our study objectives were: 
(1) to identify reliable leukocyte biomarkers; (2) to ascertain which of the reliable 
biomarkers  could discriminate[6] acutely unwell patients with suspected infection 
from patients with community acquired sepsis-related critical illness in the intensive 
care unit (ICU) and/or ED patients with non-infective acute illness requiring 
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hospitalisation; and, (3) to ascertain whether any of the reliable biomarkers with 
cross-cohort discrimination could predict which patients with suspected infection in 
the ED subsequently develop sepsis. We also undertook a post hoc extreme 
phenotype analysis[7], to compare the biomarker profiles between acutely unwell 
patients with suspected infection who subsequently developed most severe illness 
with those who recovered rapidly. 
 
Methods 
Study sites and ethics 
We performed a prospective, multi-centre, observational cohort study at four sites in 
the United Kingdom. Ethical approval was granted by the Scotland A/Oxford C 
Research Ethics Committees (13/SS/0023;13/SC/0266). Consent was provided by 
patients or surrogate decision-makers according to capacity. We registered the study 
(NCT02188992) and published the protocol including the analysis plan[8].  
Cohort definitions and eligibility criteria 
We recruited three distinct patient cohorts using an a priori sampling method to 
achieve similar age and sex profiles across the ED cohorts. Detailed 
inclusion/exclusion criteria are listed in the electronic supplement and published 
protocol (emethods-1)[8]. Cohort-1 comprised acutely unwell patients with suspected 
infection and systemic inflammation presenting to ED and formed the “discovery 
cohort”. Patients considered by clinical teams to already have established severe 
sepsis and/or require ICU admission when screened were excluded. Cohort-2 
comprised ICU patients with established community acquired sepsis-related critical 
illness and formed the “true positive” cohort. Cohort-3 comprised acutely ill patients 
presenting to ED without infection or systemic inflammation but requiring 
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hospitalization and formed the “true negative” cohort. Inclusion criteria used 
throughout the study were based on the sepsis definitions by Levy et al [9], as our 
study was designed prior to the Sepsis-3 definitions[1, 10]. All ED patients were 
enrolled within 12-hours of hospital presentation. For all cohorts, we excluded 
patients with acute pancreatitis, haematological malignancy, chemotherapy in the 
past 2-weeks, myelodysplastic syndromes, known neutropenia, HIV infection, viral 
hepatitis infection, pregnancy, blood transfusion >4units in past week, oral 
corticosteroids for >24hours prior to enrolment, or a decision not for active 
therapy/for palliative care[8].  
Leukocyte surface biomarkers and cross-site standardization of flow 
cytometry 
We devised 5 separate flow cytometry panels to assess 47 leukocyte biomarkers 
with biological plausibility for having predictive validity for subsequent sepsis 
(eMethods-1; eTable-1; eFigure-1). We developed, standardized and harmonized 
flow cytometry procedures across all 4 study sites[8]. We performed flow cytometry 
within 4-hours of sample acquisition. All anti-human antibodies conjugated to 
fluorochromes for flow cytometry were from the same batch and clones (all Becton 
Dickinson Biosciences (BDB)), standardized on the same platform (FACSCanto II; 
BDB, San Jose, CA, USA), using a common batch of Cytometry Setup and Tracking 
beads with the same beads for daily internal quality controls, at all clinical sites. All 
flow cytometry standard (FCS) files were read by expert technicians using 
standardized gating procedures developed for each biomarker prior to analysis. The 
gating strategy for estimating median fluorescence intensity (MFI) or proportions is 
reported in eMethods-1. All FCS analysis technicians were blinded from clinical data. 
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Sample size 
We based sample size estimates on the confidence interval (CI) widths for positive 
and negative predictive values (PPV and NPV). The initial design had a primary 
outcome of septic shock, with an estimated event rate of 5–10% in cohort-1[11, 12]. 
For a range in test performance for PPV/NPV of 50%-90% we planned a sample size 
of: cohort-1, n=300; cohort-2, n=100; and cohort-3, n=100, to give a CI width 
between ±4.6% to ±9.8% for PPV, and ±3.4% to ±6.3% for NPV. At an interim 
analysis of clinical event rates, the incidence of septic shock was substantially lower 
than anticipated. We decided by consensus to change the primary outcome to 
severe sepsis (and subsequently adopted the sepsis-3 sepsis criteria[1] of 
Sequential Organ Failure Assessment (SOFA) score ≥2), with critical care admission 
a key secondary outcome, to ensure adequate clinically relevant events in the 
discriminant analyses. These changes occurred prior to study completion and were 
reported in the published protocol[8].  
Statistical analysis 
The primary study cohort was cohort-1. The primary exposure was suspected 
infection. The cohorts-2 and 3 were comparator populations for cross-cohort 
discrimination and biomarker selection.    
Outcomes 
The primary outcome was sepsis, defined as SOFA score ≥2 at 24 hours and/or 72 
hours following presentation to hospital in patients with suspected infection in the ED 
(cohort-1)[1]. Secondary outcomes were: critical care admission or death within 72 
hours of presentation; SOFA ≥4 at 24 hours and/or 72 hours following presentation 
to hospital; development of septic shock; discharge home within 72 hours; discharge 
to home or in hospital with no organ failure within 72 hours; death from sepsis; 
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confirmed infection and length of hospital stay[8]. All cohort-1 data are based on 
blood samples taken in the ED after recruitment. 
Biomarkers selection strategy 
Our analytic approach to discover biomarkers with potential diagnostic discrimination 
for risk of subsequent sepsis occurred in three a priori planned stages, and one post-
hoc analysis.  
Stage one: reliability 
Inter- and intra-reader reliability for 47 different biomarkers was established 
according to the protocol[8]. To be included in subsequent evaluation stages 
biomarkers needed to demonstrate both inter- and intra-reader reliability at the pre-
defined intra-class correlation coefficient (ICC) between readers ≥0.9; see Figure-1 
and eMethods-2; eTable-2). For intra-reader reliability the ICC for each reader was 
calculated as the ratio of within-reader variability to the total variance (within-reader 
plus residual variance) from the normal linear mixed model. For inter-reader 
reliability the ICC was calculated as the ratio of between-reader variability to the total 
variance (between-reader plus residual variance) from the normal linear mixed 
model. Reliability analyses were done prior to linking leukocyte biomarkers data and 
clinical outcome data. 
Stage two: cross-cohort discrimination 
For reliable biomarkers, statistically significant inter-group differences between the 
three cohorts were explored using Kruskal-Wallis analysis of variance (ANOVA) tests 
(eTable-3) and visual inspection of data. Biomarkers that discriminated between 
cohort-1 and either cohort-2 (true-positive) and/or cohort-3 (true negative) and had 
variability within cohort-1 consistent with potential to discriminate clinical outcomes 
were selected for Stage-3 analysis. Other factors considered were cell counts, the 
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magnitude of MFI, and potential linkage and co-linearity between groups of 
biomarkers. This was done in consensus meetings by researchers blinded from 
clinical outcomes within cohort-1. 
Stage three: Prediction of clinical outcomes in cohort-1 
Within cohort-1 patients, the ability of the selected biomarkers to predict the primary 
and secondary outcomes was calculated using univariate logistic regression. For the 
secondary outcomes of death from sepsis, septic shock and length of stay, we 
provided a descriptive summary as per the analysis plan[8]. The odds ratio (OR) for 
the outcome per standard deviation increase in biomarker, Receiver Operating 
Characteristic (ROC) curves, and area under ROC curve (AUROC) were used to 
assess predictive ability. Youden’s index identified the optimal cut-off point for each 
marker[13]. Candidate biomarkers that showed consistent inclusion were then taken 
forward for multivariable modelling.   
We used best subsets regression[14] to identify optimal combinations of predictive 
markers.  Specifically, models containing a given number of biomarkers were fitted 
for all potential biomarker combinations.  The five best-fitting models of a given size, 
according to the chi-squared score statistic, were identified.  Biomarkers which 
consistently appeared in the best-fitting models were selected for the final model.  
The change in chi-squared score statistic between the best fitting models containing 
different numbers of biomarkers was used to determine the number of biomarkers to 
be included in the final model. Linearity of biomarker associations on the logistic 
scale was checked using plots of deviance residuals. Based on consistency and 
model fit we identified optimal combinations of predictive markers. 
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Post hoc extreme phenotype comparison 
On the recommendation of a pre-planned independent expert group (see eTable-4), 
we compared biomarker profiles between sub-populations within cohort-1 with 
extreme clinical phenotypes of organ dysfunction and outcome to further explore 
associations for the biomarkers evaluated. We defined well and sick extreme 
phenotypes[7], by consensus among clinical investigators using clinical data without 
knowledge of group differences in biomarkers (eFigure-2). The well phenotype had 
no positive microbiology, a SOFA score ≤2 at 24 and 72 hours post-enrolment and 
were either discharged home by 72 hours or were in hospital but no longer receiving 
antibiotics. The sick phenotype had a confirmed infection, SOFA score ≥2 at both 24 
and 72 hours post-enrolment and were still in hospital and receiving antibiotics at 72 
hours. We compared biomarker expression between the two phenotypes using two-
sample t-tests or Mann Whitney tests as appropriate, applying Bonferroni correction 
for multiple testing. 
For additional comparison, we also measured C-reactive protein (CRP) and 
Procalcitonin (PCT) concentrations at the same time point for Cohort-1 patients, 
given the widespread clinical use of these biomarkers in assessing infection. We 
constructed ROC curves for CRP and PCT and estimated similar univariate 
predictive performance characteristics of these for outcomes reported, to enable 
direct comparison of predictive validity with the more novel biomarkers. 
 
Results 
Patient characteristics 
Between January 2014 and February 2016, we recruited 272, 59 and 75 patients 
(N=406) to cohorts 1, 2, and 3 respectively. The clinical characteristics for the three 
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cohorts and the cohort-1 outcomes are shown in Table-1. Cohorts-1 and 3 had a 
similar age and sex distribution. Cohort-2 patients tended to be older. The primary 
outcome in cohort-1, clinical deterioration to sepsis, occurred in 139 patients 
(51.1%).  
Stage one: Reliability 
The step-wise assessment of intra-reader and then inter-reader reliability resulted in 
rejection of 14 biomarkers as non-reliable, leaving 33 reliable biomarkers for cross-
cohort comparison (Figure-1; eTable-2). 
Stage two: Cross-cohort discrimination 
Statistical comparison, expert review, and cohort-1 data distribution resulted in 
rejection of a further 17 biomarkers (Figure-1; eTable-2; eTable-3). The cross-cohort 
comparisons plots for the 16 selected biomarkers are shown in eFigure-3. Based on 
the stage-1 and two selections, eight neutrophil biomarkers (cluster of differentiation 
antigens (CD) CD15;CD24;CD35;CD64;CD312;CD11b;CD274;CD279), seven 
monocyte biomarkers (CD35;CD64;CD312;CD11b;HLA-DR;CD274;CD279) and one 
CD8 T-lymphocyte biomarker (CD279) were selected for evaluation of discrimination 
for clinical outcomes. Biological relevance of these markers in sepsis are 
summarized in Table-2. 
Stage three: Prediction of clinical outcomes in cohort-1 
Most biomarkers lacked any clinically or statistically significant discrimination for 
predicting primary and secondary outcomes within cohort-1 patients. Amongst the 
individual biomarkers, clinical deterioration to sepsis was associated with higher 
neutrophil CD279 expression, higher monocyte CD279 expression and lower 
monocyte HLA-DR expression. The optimal MFI cut off for neutrophil CD279 was 
239 (sensitivity 0.88 (95% confidence interval:0.82 – 0.93); specificity 0.35(0.26 – 
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0.43); for monocyte CD279 was 141 (sensitivity 0.83(0.77 – 0.90); specificity 
0.39(0.30 – 0.47); and for monocyte HLA-DR was 3572 (sensitivity 0.43(0.34 – 0.51); 
specificity 0.69(0.60 – 0.77). Although these associations were statistically 
significant, discriminant ability was poor and unlikely to be clinically useful in 
isolation.  
With best subsets logistic regression, the optimum combination for predicting clinical 
deterioration to sepsis included increased neutrophil CD24; increased neutrophil 
CD279; and reduced monocyte HLA-DR expression (sensitivity 0.72(0.64 – 0.79); 
specificity 0.56(0.48 – 0.65). With best subsets logistic regression, the optimum 
combination for predicting the secondary outcome of discharge to home within 72 
hours, included increased neutrophil CD15, reduced neutrophil CD274 and 
increased total monocyte HLA-DR expression. No biomarkers had significant 
discriminant value for the outcome of critical care admission or death within 72 
hours. The performance of individual and optimized combinations of biomarkers for 
predicting the primary and secondary outcomes, are shown in Table-3. No marked 
non-linearities in biomarker effects were identified. Overall, although statistically 
significant associations were demonstrated, discrimination of clinical outcomes was 
unlikely to be clinically useful.  
Extreme phenotype analysis 
From 272 patients in cohort-1, we identified 40 ‘well’ and 52 ‘sick’ phenotypes 
(eFigure-2). ‘Sick’ phenotype patients were characterized by being older, more often 
male, with a higher frequency of co-morbidities, more frequently lymphopenic, with 
higher APACHE II and SOFA scores at baseline. After Bonferroni correction for 
multiple comparisons, ‘sick’ phenotypes had significantly higher monocyte CD279 
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and neutrophil CD279 in the ED, but no other biomarkers were different (Table-3; 
eFigure-4). 
For both CRP and PCT, there was also no statistically or clinically significant 
discrimination for subsequent sepsis with univariate analysis (Table-3). 
 
Discussion 
In this multi-site cohort study, we reduced a candidate panel of 47 leukocyte 
biomarkers to 16 reliable biomarkers with potential for discriminating the risk of 
developing sepsis in patients with suspected infection presenting to the ED. The 
combination of higher neutrophil CD24, higher neutrophil CD279, and a lower 
monocyte HLA-DR expression best predicted the clinical deterioration to sepsis. 
Consistent with this association, a lower neutrophil CD279 expression and higher 
monocyte HLA-DR expression were associated with discharge home within 72 hours 
(implying rapid recovery). Although our pre-defined biomarker discovery strategy 
identified these biomarkers as associated with development of sepsis and more 
severe illness, their discriminant value was insufficient to suggest utility for decision-
making in routine clinical care.  
Our findings have potential clinical relevance. The key pathophysiological insight is 
that leukocyte biomarkers of immunosuppression such as check-point inhibitors 
(CD279; CD274) and antigen processing ability (HLA-DR) were altered even in 
patients with suspected infection presenting to ED. We also demonstrate the 
importance of assessing reliability when standardising flow cytometry for large-scale 
time critical use. The development of clinically useable tests is likely to require a form 
of cross-platform calibration (such as multiparametric version of the Quantibrite 
system, BD Bioscience). Our study shows it is feasible to implement flow cytometry 
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as a means of undertaking precision medicine in sepsis, for example to guide novel 
therapeutic interventions such as those tested recently in immunotherapy trials [15] 
and highlighted in recent expert reviews [16, 17]. However, our data suggest that for 
patients with suspected infection the predictive validity of panels of leukocyte 
biomarkers are unlikely to be useful as general clinical decision-making tools. Of 
note, both CRP and PCT also performed poorly. 
Strengths of our study were well-defined hypothesis, pre-published protocol [8], 
internationally accepted primary outcome [1], clinically relevant secondary outcomes 
and hierarchical analytic approach to reduce biomarker selection bias. Reliability of 
multi-site flow cytometry is potentially problematic due to measurement error bias 
[18], which we addressed rigorously with fluorochrome-conjugated antibody titrated 
for optimal signal and kept constant throughout the study. Using hospitalized non-
infected patients and ICU-sepsis patients as comparators during biomarker selection 
increased the chance of detecting infection related host responses and is superior to 
using healthy volunteer controls. Our blood sampling time point in the ED was prior 
to severe illness, before major clinical interventions, and much earlier than in 
previous studies of sepsis biomarkers, and we excluded patients who clinicians 
considered already had established sepsis and/or critical illness. As such our 
population was different from other recent studies, which evaluated leukocyte 
biomarkers for prediction of sepsis trajectory (by including patients with sepsis-2 
defined sepsis, severe sepsis and septic shock) [19, 20] and stratified nosocomial 
infection risk in ICU patients[21] (see eTable-5 that highlights important differences). 
The post-hoc extreme phenotype analysis enhanced face validity by considering 
multiple clinical variables simultaneously for phenotype definition. 
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Our study has potential weaknesses. Although we could not include all potential 
leukocyte biomarkers, we studied a range of leukocyte biomarkers (such as 
complement pathway receptors (CD35, CD11b), G protein-coupled receptors 
(CD312), Fc-gamma-receptors (CD64[22, 23]), factors delaying neutrophil apoptosis 
(CD24[22]), check-point molecules (CD274, CD279)[24]; HLA-DR expression [25-
27]), that previous studies highlight association with adverse outcomes in 
established sepsis. We enrolled a smaller sample size than planned due to time and 
funding constraints.  However, this had a limited impact since substantial differences 
in biomarker levels across cohorts still enabled selection of candidate biomarkers for 
further discriminant analysis. Supervised classification methods such as 
classification and regression trees (CART) is a valid alternative analytic approach for 
this research question. However, CART requires approximately 50 events per 
variable when predicting a dichotomised outcome,  before predictions become stable 
and over-optimism is minimised [28].  As our observed number of sepsis events did 
not reach this threshold we opted to use the best subsets logistic regression 
approach as pre-specified in our statistical analysis plan [8].  As our cohort-1 
inclusion criteria mandated SIRS, we have excluded SIRS negative patients with 
infection, who could have progressed to develop sepsis. However, this is unlikely to 
bias the results, as the prevalence of SIRS negative sepsis-3 sepsis in ICUs in 
England is only 3% [29]. As our objective was to study leukocyte biomarkers at an 
earlier time point than previously achieved and to identify biomarkers that predict 
deterioration within 72 hours of hospitalisation, we excluded patients planned for 
direct admission to ICU from the ED at enrolment, which explains the lower than 
expected event rate for death and septic shock. Findings might be different for more 
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severely ill patients studied later in sepsis, as observed in other recent flowcyometric 
studies (eTable-5) [19-21].  
 
Our findings have biological plausibility, as the leukocyte biomarkers that best 
predicted the risk of developing sepsis in our study were on the key innate immune 
cells, namely neutrophils and monocytes, which are first responders to infection. The 
strongest biomarker predicting subsequent sepsis and extreme phenotypes was 
higher levels of CD279 (programmed death receptor 1, PD-1) on monocytes and 
neutrophils. CD279 expression is associated with neutrophil and monocyte 
suppressor subsets [30], memory lymphocyte subsets [31], is thought to regulate T-
cell responses and induce an inhibitory signal characterized by cell cycle arrest and 
reduced cytokine synthesis [2, 32]. This early role for CD279/PD-1 is consistent with 
animal models of sepsis [33] and sepsis cohorts [30]. CD279/PD-1 act in conjunction 
with its ligand CD274 (PD-L1). In our study, lower CD274, together with lower 
CD279, higher monocyte HLA-DR, and lower neutrophil CD24, emerged as a 
predictor for rapid recovery sepsis phenotype. These novel findings require further 
confirmatory studies.  
Although none of the biomarkers we studied had discriminant ability that could be 
used to guide clinical decision-making, our data implies that immunosuppression in 
infected patients precedes established sepsis and that higher CD279/PD-1 and 
lower HLA-DR are potential theragnostic and enrichment markers [34-37] for anti-
PD-1/PDL-1 agents and granulocyte-monocyte colony stimulating factor[25] 
respectively, for carefully designed immunotherapy trials [3, 38].  
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Conclusions 
We conclude that in a population of patients presenting with suspected infection, 
prior to established sepsis, a sequential approach to identifying reliable potential 
leukocyte biomarkers from a large candidate panel that may predict the subsequent 
development of sepsis identified only a small number with discriminant properties.  
These were markers of immune suppression, namely CD279 and HLA-DR, 
suggesting this may be an early event, prior to development of sepsis. 
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1 
TABLES 
Table-1: Cohort characteristics and outcomes 
 
 Cohort-1 (Infected ED 
cohort) 
N=272 
Cohort-2 (ICU-septic) 
N=59 
Cohort-3 (non-infected 
ED controls) 
N=75 
 
Cohort characteristics 
Age in years mean (SD) 62.1 (19.1) 67.9 (12.8) 61.6 (20.0) 
Female N (%) 133 (48.9%) 23 (39.0%) 33 (44.0%) 
FCI Score Median (IQR) 2 (1,3) 2 (1,4) 1 (0,2) 
White cell count Median (IQR) 
- Total 
- Neutrophils 
- Lymphocytes 
 
13.5 (10.7, 16.2) 
11.2 (  8.5, 14.1) 
  0.9 (  0.6,   1.4) 
 
16.9 (10.1, 19.6) 
14.1 (  8.2, 17.5) 
  0.9 (  0.6,   1.3) 
 
7.7 (6.4, 9.1) 
4.9 (4.1, 6.4) 
1.7 (1.3, 2.1) 
C-reactive protein Median (IQR) 
Procalcitonin Median (IQR) 
64 (21,168) 
29.4 (0.0, 337.3) 
212 (86,309) 
No data 
13 (2,27) 
No data 
Confirmed infection 238 (87.5%) 59 (100%) 0 
qSOFA score >=2 
- at ED presentation 
- at 24 hours 
- at 72 hours 
 
44 (16.2%) 
  6 (  2.2%) 
  5 (  1.8%) 
 
No data 
 
No data 
APACHE II score 
Median (IQR) 
9 (6,13) 16 (12,21) 6 (3,9) 
SOFA score 
Median (IQR) 
2 (1,3) 7 (5,9) 1 (1,2) 
Site of infection N(%) 
- Respiratory 
- Urinary 
- Unknown 
- Musculoskeletal, skin and soft tissue 
- Abdominal (including biliary) 
- Neurological 
 
124 (45.6%) 
44 (16.2%) 
40 (14.7%) 
32 (11.7%) 
28 (11.0%) 
4 (1.5%) 
  
 
Outcomes for Cohort-1 
 
Primary outcome1 
- SOFA>=2 at 24 or 72 hours 
 
 
139 (51.1%) 
  
 
Secondary outcomes 
 
- ICU admission or death within 72 hours 
of hospitalization 
- SOFA>=4 at 24 or 72 hours 
- Discharged home within 72 hours of 
hospitalization 
- Discharged home or in hospital with no 
organ failure 
- Hospital mortality N (%) 
- Development of septic shock 
 
 
   
  22 (8.1%) 
 
  36 (13.2%) 
  86 (31.6%) 
 
148 (54.4%) 
 
    1 (0.4%) 
    1 (0.4%) 
  
Organ support 
- On antibiotics at 72 hours 
- Vasopressors 
- Ventilation invasive 
- Ventilation non-invasive 
 
144 (52.9%) 
    2 (0.7%) 
    2 (0.7%) 
    5 (1.8%) 
  
Hospital length of stay (days)  
Median (IQR) 
5 (2, 9)   
 
 
 
 
 
1 
Table-2: Biological relevance in sepsis patients of the reliable cell surface markers with discriminant value identified in 
Cohort-1 
Cell surface 
markers 
Marker positive 
leukocytes in our 
study 
Biological relevance in sepsis[2, 3, 25, 32, 39-43] Our key inferences  
CD15 Neutrophil Expressed on all myeloid cells and from the promyelocyte stage onwards on 
neutrophils. Although monocytes express CD15 at low levels, we were gating 
CD15hi granulocytes. 
Alongside CD14, CD16, CD11b, CD15, is a marker for myeloid derived suppressor 
cells[44, 45], which is implicated in supressing T cell function. 
CD24 Neutrophil Expressed on mature granulocytes and B cells; down-regulated on neutrophils in 
sepsis, induces neutrophil apoptosis which is delayed in sepsis. 
CD16 low/CD14 negative / CD24 positive myeloid-derived suppressor cells are 
cytotoxic to T cells[20]. Immature granulocytes in peripheral circulation in sepsis is 
associated with greater risk of death[46]. 
CD35 Neutrophil 
Monocytes 
Receptors of complement activation (RCA) family expressed on leukocytes; 
potentially discriminates sepsis from inflammation 
Understanding of major roles of CD35 alterations in sepsis is unclear. 
CD64 Neutrophil 
Monocytes 
Fc gamma receptor expressed on leukocytes; Patients with sepsis have increased 
expression of CD64 has been consistently reported. 
Despite this association, CD64 as a single marker has limited diagnostic 
performance in sepsis [23, 41]. 
CD11b Neutrophil 
Monocytes 
Role in adhesive interactions of monocytes, macrophages and granulocytes; 
mediating the uptake of complement-coated particles; increased in sepsis following 
neutrophil activation 
Neutrophil and monocyte increase in CD11b is inconsistent in the literature[47, 48]. 
Tissue resident CD11b positive T cells, secrete interferon gamma and may influence 
local host defence mechanisms in bacterial infections[49].  
CD312 Neutrophil 
Monocytes 
human myeloid-restricted class B seven-span transmembrane (TM7) subfamily of 
G-protein coupled receptors; acutely altered in sepsis secondary to leukocyte 
activation 
Understanding of major roles of CD312 alterations in sepsis is unclear. 
CD274 Neutrophil 
Monocytes 
PD-1 and PDL-1 form a check point inhibitor complex and are considered markers 
of sepsis related immunosuppression. In sepsis, neutrophils, monocytes and 
lymphocytes express elevated levels of with CD274 and CD279[2, 30, 31]. In 
sepsis, neutrophils are thought to impair T cell function through PD-L1 
mechanism[33, 50]. 
Recently, it has been shown that the increasing functional deficit in multiple innate 
and adaptive immune responses in sepsis-related critical illness could be restored ex 
vivo in cells treatment with monoclonal antibodies targeting either arm of the PD-
1:PD-L1 axis [30, 50]. Thus, measuring cellular levels of PD-1 and PD-L1 could 
inform trial design. 
CD279 Neutrophil 
Monocytes 
CD-8 T cells 
HLA-DR Monocyte Consistently reported as a marker of immunosuppression in sepsis and in critically 
ill patients 
Reduced HLA-DR expression on monocytes is associated with increased risk of 
nosocomial infection due to impaired monocyte competence. Monocyte HLA-DR 
expression less than 8000 monoclonal antibodies/cell for 2 or more days can be 
reversed with GM-CSF therapy, with potentially beneficial effects [25]. This is a 
useful biomarker for enrichment in future clinical trials. 
 
 
 
 
1 
Table-2: Candidate biomarkers and combinations for predicting outcomes in cohort-1 
Biomarker Marker expression in 
cohort-1 as  
Median MFI (IQR) 
Primary outcome  
[OR (95% CI) per SD increase in MFI; p 
value] 
Secondary outcomes1  
[OR (95% CI) per SD increase in MFI; p value] 
SOFA score ≥2 at 24 
hours and/or 72 hours 
following presentation 
to hospital2 
AUROC (95% CI) ICU admission or 
death within 72 hours 
of presentation 
 
SOFA>=4 at 24 or 72 
hours after 
presentation 
 
Discharge home within 
72 hours of 
presentation 
Discharge home within 
72 hours of 
presentation or in-
hospital with no organ 
failure 
Confirmed infection 
Neutrophils 
- CD15 
- CD24 
- CD35 
- CD64 
- CD312 
- CD11b 
- CD274 
- CD279 
 
31148 (22261, 39622) 
22261 (16398, 28565) 
17363 (10021, 26452) 
  2384   (1353, 5522) 
    685     (451, 845) 
20583 (13210, 28737) 
    269     (207, 320) 
    569     (300, 640) 
 
0.94 (0.69 – 1.28); 0.70 
1.20 (0.94 – 1.54); 0.15 
0.98 (0.77 – 1.25); 0.87 
0.95 (0.71 – 1.29); 0.75 
1.29 (0.99 – 1.67); 0.06 
1.25 (0.97 – 1.62); 0.08 
1.25 (0.96 – 1.61); 0.10 
1.78 (1.23 – 2.57); 0.002 
 
0.50 (0.41 –0.59) 
0.56 (0.49 – 0.63) 
0.51 (0.44 – 0.58) 
0.49 (0.41 – 0.58) 
0.57 (0.50 – 0.64) 
0.56 (0.49 – 0.63) 
0.57 (0.50 – 0.64) 
0.59 (0.52 – 0.66) 
 
 
1.36 (0.82 – 2.22); 0.23 
1.26 (0.84 – 1.90); 0.17 
1.18 (0.76 – 1.83); 0.45 
0.98 (0.55 – 1.75); 0.94 
0.74 (0.43 – 1.29); 0.29 
1.45 (0.97 – 2.16); 0.07 
0.91 (0.55 – 1.49); 0.70 
0.96 (0.57 – 1.61); 0.86 
 
1.01 (0.65 – 1.58); 0.97 
1.48 (1.08 – 2.05); 0.01 
0.90 (0.62 – 1.31); 0.59 
0.88 (0.53 – 1.45); 0.61 
0.82 (0.55 – 1.23); 0.34 
1.36 (0.98 – 1.60); 0.57 
1.16 (0.83 – 1.61); 0.39 
1.06 (0.77 – 1.46); 0.72 
 
1.38 (0.99 – 1.91); 0.06 
1.00 (0.77 – 1.30); 1.00 
1.18 (0.91 – 1.53); 0.21 
0.97 (0.70 – 1.33); 0.83 
0.79 (0.59 – 1.06); 0.12 
1.12 (0.86 – 1.45); 0.39 
0.70 (0.51 – 0.95); 0.02 
0.57 (0.39 – 0.83); 0.003 
 
1.13 (0.83 – 1.56); 0.42 
0.79 (0.62 – 1.02); 0.07 
1.15 (0.90 – 1.47); 0.28 
0.95 (0.71 – 1.28); 0.74 
0.85 (0.67 – 1.09); 0.21 
0.84 (0.66 – 1.08); 0.18 
0.77 (0.59 – 0.99); 0.045 
0.60 (0.41 – 0.87); 0.007 
 
0.89 (0.57, 1.41); 0.63 
1.31 (0.85, 2.04); 0.22 
1.34 (0.88, 2.06); 0.17 
1.62 (0.84, 3.12); 0.15 
1.10 (0.73, 1.67); 0.64 
1.27 (0.83, 1.96); 0.27 
1.56 (0.97, 2.52); 0.07 
1.06 (0.68, 1.66); 0.78 
Monocyte 
- CD35 
- CD64 
- CD312 
- CD11b 
- HLA-DR 
- CD274 
- CD279 
 
21018 (13818, 28565) 
30848 (24499, 39622) 
  1087     (649, 1617) 
22705 (14413, 28651) 
  4435   (2379, 8001) 
      60     (0, 166) 
    240       (129, 280) 
 
1.15 (0.89 – 1.48); 0.28 
1.04 (0.77 – 1.39); 0.80 
0.91 (0.71 – 1.16); 0.43 
1.21 (0.94 – 1.57); 0.14 
0.73 (0.55 – 0.97); 0.03 
0.90 (0.70 – 1.16); 0.41 
1.32 (1.03 – 1.70); 0.03 
 
 
0.55 (0.48 – 0.62) 
0.57 (0.49 – 0.66) 
0.54 (0.47 – 0.61) 
0.58 (0.51 – 0.65) 
0.56 (0.49 – 0.63) 
0.50 (0.43 – 0.56) 
0.58 (0.51 – 0.65) 
 
 
0.99 (0.62 – 1.57); 0.95 
1.25 (0.77 – 2.03); 0.36 
0.73 (0.41 – 1.29); 0.29 
1.25 (0.83 – 1.88); 0.28 
0.69 (0.34 – 1.40); 0.30 
1.06 (0.69 – 1.61); 0.80 
0.89 (0.56 – 1.43); 0.31 
 
 
1.33 (0.97 – 1.83); 0.07 
1.12 (0.74 – 1.71); 0.59 
0.79 (0.52 – 1.21); 0.28 
1.27 (0.91 – 1.76); 0.16 
0.76 (0.46 – 1.24); 0.27 
1.03 (0.73 – 1.46); 0.85 
1.21 (0.84 – 1.75); 0.27 
 
 
0.91 (0.70 – 1.20); 0.52 
0.95 (0.69 – 1.30); 0.73 
1.24 (0.96 – 1.61); 0.09 
1.15 (0.89 – 1.49); 0.30 
1.35 (1.04 – 1.75); 0.02 
0.84 (0.62 – 1.15); 0.28 
0.68 (0.52 – 0.90); 0.006 
 
0.94 (0.73 – 1.20); 0.60 
0.92 (0.69 – 1.24); 0.58 
1.06 (0.83 – 1.36); 0.64 
0.87 (0.68 – 1.12); 0.27 
1.34 (1.00 – 1.80); 0.052 
0.99 (0.78 – 1.27); 0.95 
0.80 (0.62 – 1.02); 0.07 
 
1.19 (0.77, 1.84); 0.44 
2.24 (1.11, 4.52); 0.02 
0.94 (0.65, 1.36); 0.73 
1.24 (0.80, 1.93); 0.33 
0.96 (0.66, 1.38); 0.82 
0.89 (0.64, 1.23); 0.48 
0.98 (0.67, 1.44); 0.92 
CD8 T cells 
- CD279 
    117     (72, 169)  
1.16 (0.81 – 1.66); 0.43 
 
0.48 (0.41 – 0.55) 
 
0.23 (0.02 – 2.29); 0.21 
 
0.94 (0.58 – 1.93); 0.80 
 
0.79 (0.43 – 1.45); 0.45 
 
0.82 (0.55 – 1.23); 0.34 
 
2.00 (0.44, 9.06); 0.37 
Neutrophil 
CD24 + 
Neutrophil 
CD279 
 
Neutrophil 
CD24 + 
Neutrophil 
CD279 +  
Monocyte HLA-
DR 
 
Neutrophil 
CD15 + 
Neutrophil 
CD274 +  
Monocyte HLA-
DR 
  
1.48 (1.10 –1.98); 0.009 
2.23 (1.47 –3.38); <0.001 
 
 
1.49 (1.10 –2.00); 0.009 
2.37 (1.54 –3.64); <0.001 
0.72 (0.53 – 0.97); 0.03 
0.64 (0.58 – 0.71) 
 
 
 
0.67 (0.60 – 0.74) 
 
* 
 
* 
 
 
 
 
 
 
 
 
 
 
 
1.32 (0.94 –1.85); 0.10 
0.59 (0.41 –0.86); 0.006 
1.48 (1.03 – 2.13); 0.04 
 
0.65 (0.49 – 0.87); 0.004 
0.47 (0.31 – 0.71); 
0.0004 
 
* 
Other markers# 
CRP 
PCT 
 
 
 
1.20 (0.94 – 1.54): p=0.15 
0.94 (0.72 – 1.21); p=0.61 
 
0.56 (0.49, 0.63) 
0.53 (0.46, 0.60) 
 
0.88 (0.55 – 1.42); 0.60 
0.93 (0.54 – 1.61); 0.57 
 
0.99 (0.69 – 1.42); 0.94 
0.81 (0.48 – 1.36); 0.42 
 
0.74 (0.55 – 0.99); 0.04 
0.83 (0.60 – 1.15); 0.27 
 
0.85 (0.66 – 1.08); 0.19 
1.02 (0.79 – 1.32); 0.89 
 
1.16 (0.99 – 2.65); 0.06 
4.00 (0.78 – 20.5); 0.10 
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Table-4: Extreme phenotype description 
 
 
 
 
 
 
Well phenotype 
(N = 40) 
Sick phenotype 
(N = 52) 
p-value 
Age, median (IQR) 37.5 (27.3 – 56.8) 70.0 (56.0 – 81.0) <0.001 
Female, n (%) 26 (65%) 19 (37%) 0.009 
FCI Score Median (IQR) 1 (0 – 2) 2 (1 – 3) 0.03 
White cell count Median (IQR) 
Total 
Neutrophils 
Lymphocytes 
 
13.2 (10.3 – 14.4) 
10.3 (8.1 – 12.0) 
1.2 (0.7 – 1.8) 
 
13.1 (9.1 – 16.5) 
11.2 (7.5 – 15.1) 
 0.8 (0.5 – 1.2) 
 
0.78 
0.29 
0.01 
C-reactive protein  
Median (IQR) 
58.5 (24.0 – 107.3) 56.0 (16.5 – 191.0) 0.85 
qSOFA score >=2  
at ED presentation 
at 24 hours 
at 72 hours 
 
3 (7.5%) 
0 
0 
 
10 (19.2%) 
4 (7.7%) 
2 (3.8%) 
 
0.11 
0.07 
0.22 
Source of infection*, n (%) 
Respiratory 
Neurological 
Urinary 
Abdominal 
Skin 
Biliary 
Sepsis of unknown origin 
 
13 (40.6 %) 
1 (3.1%) 
2 (6.3 %) 
5 (15.6 %) 
9 (28.1 %) 
0 (0%) 
2 (6.3 %) 
 
30 (57.7%) 
2 (3.8%) 
7 (13.4%) 
5 (9.6%) 
3 (5.8%) 
5 (9.6%) 
0 (0%) 
 
0.13 
0.87 
0.31 
0.41 
0.005 
0.005 
0.07 
Baseline APACHE 2 score, median (IQR) 4.5 (2-7) 11.5 (9-16) <0.001 
Baseline SOFA, median (IQR) 1 (1-1) 3 (2-4) <0.001 
Discharged home within 72 hours, n (%) 32 (80%) 0 <0.001 
Admitted to HDU/ICU within 72 hours, n (%) 0 14 (26.9%) <0.001 
Neutrophil biomarkers (MFI) median (IQR) 
Neutrophil CD15  
Neutrophil CD24 
Neutrophil CD35 
Neutrophil CD64 
Neutrophil CD312 
Neutrophil CD11b 
Neutrophil CD27s 
Neutrophil CD279 
 
30848 (24499 – 45352) 
23815 (18299 – 29261) 
19485 (7985 – 26580) 
3098 (1528 – 6272) 
565.8 (382.7 – 712.9) 
16089 (13664 – 25552) 
279.0 (101.4 – 322.8) 
326.4 (152.7 – 584.2) 
 
30848 (19116 – 41992) 
24034 (18741 – 30710) 
15636 (10988 – 25117) 
2150 (1693 – 5378) 
670.9 (493.6 – 853.9) 
22154 (13510 – 30737) 
284.3 (233.8 – 327.7) 
584.2 (383.7 – 648.8) 
 
>0.10 
>0.10 
>0.10 
>0.10 
>0.10 
>0.10  
>0.10 
0.005 
Monocyte biomarkers (MFI) median (IQR) 
Monocyte CD35 
Monocyte CD64 
Monocyte CD312 
Monocyte CD11b 
Monocyte CD274 
Monocyte CD279 
Monocyte HLA-DR 
 
16556 (9974 – 27488) 
29685 (21843 – 45021) 
1243 (694 – 2001) 
20205 (12102 – 26644) 
50.7 (0 – 167.2) 
151.2 (94.8 – 262.1) 
6172 (3516 – 11544) 
 
22476 (15067 – 27681) 
33323 (29405 – 45352) 
817.0 (470.5 – 1560.0) 
26660 (16984 – 32741) 
78.6 (0 – 199.7) 
245.4 (161.1 – 287.0) 
4016 (2692 – 7170) 
 
>0.10 
>0.10 
>0.10 
>0.10  
>0.10 
0.05 
0.12 
CD-8 T cell biomarker (MFI) median (IQR) 
CD8 T-Lymphocyte CD279 
 
112.2 (78.7 – 153.3) 
 
115.6 (58.5 – 167.9) 
 
>0.10 
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Online only supplement 
Shankar-Hari M et al. Early PREdiction of Sepsis using leucocyte cell surface 
biomarkers: The (ExPRES-Sepsis) cohort study 
 
eMethods 
eMethods-1: Detailed study cohort description1 and description of gating with rationale 
eMethods-2: Reliability and optimisation 
 
eTables 
eTable-1: Leukocyte biomarkers evaluated  
MFI = mean fluorescence index; CD = Cluster of differentiation;  
 
eTable-2: Table of Intraclass correlation coefficients (ICC) from the intra- and inter-rater 
reliability studies for each of the 47 biomarkers. Biomarkers rejected on intra-rater reliability 
testing are shown in red. Biomarkers rejected on inter-rater reliability testing are shown in 
blue 
 
eTable-3: Rationale for Biomarkers selected for discriminant analysis in cross cohort 
comparison 
 
eTable-4: Members of the independent expert review group who reviewed the provisional data 
from reliability, cross cohort comparisons, and discriminant analysis for the primary and 
secondary outcomes. 
 
eTable-5: Comparison of recent leukocyte biomarker studies using multi-site 
flow cytometry with standardisation for illness trajectory prediction 2-4 
 
 
eFigures 
eFigure-1: Flow diagram showing the decision analysis for assessing intra- and inter-rater 
reliability for the 47 biomarkers, and selecting biomarkers considered reliable for evaluation in 
cross cohort comparisons, as reported in the published protocol. 
 
eFigure-2: Extreme phenotype derivation algorithm 
 
eFigure-3: Cross cohort comparison of significant markers taken forward for further 
evaluation 
 
eFigure-4: Comparison of biomarkers between sick phenotype, and well phenotypes 
Shows significant differences in neutrophil CD279 between sick and well phenotype. MFI = Median 
Fluorescence intensity, reported on log10 scale. Statistical significance was determined using the 
Bonferroni-Dunn method to correct for multiple testing, with alpha = 0.05. 
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eMethods-1: Detailed study cohort description 
This was reported in the published protocol paper and is replicated here for completion1. 
We recruited three distinct patient cohorts: 
Cohort 1: Patients presenting to hospital with suspected infection with a systemic inflammation 
(discovery cohort). 
Cohort 2: hospitalised patients with community-acquired severe sepsis requiring treatment in critical 
care (true- positive cohort).  
Cohort 3: patients presenting with no suspicion of infection or systemic inflammation, needing 
hospitalisation (‘non-sepsis comparison population’).  
Inclusion criteria  
Cohort 1  
Age ≥16 years (≥18 years in England), (2) SIRS criteria met, (3) clinical suspicion of sepsis (blood 
cultures and/ or other samples taken for microbial culture, or antibiotics started by clinical team), (4) 
no clinical suspicion of severe sepsis or septic shock at the time of enrolment and (5) enrolled within 
12hours of hospital (ED) presentation.  
Cohort 2  
Age ≥16 years (≥18 years in England), (2) SIRS criteria met, (3) clinical suspicion of sepsis (blood 
cultures and/ or other samples taken for microbial culture, or antibiotics started by clinical team), (4) 
severity of sepsis requiring critical care admission (based on decision of caring clinical teams), (5) 
enrolled within 72 hours of hospital admission and (6) not enrolled into cohort 1 of ExPRES-Sepsis.  
Cohort 3  
Age ≥16 years (≥18 years in England), (2) does not meet SIRS criteria, (3) no clinical suspicion of 
sepsis (blood cultures and/or other samples NOT taken for microbial culture, and antibiotics NOT 
started by clinical team), (4) patient expected to be admitted to hospital, (5) patient NOT expected to 
die during hospital admission.  
Exclusion criteria (for all cohorts)  
Exclusions were chosen to ensure conditions that provoke a sterile inflammatory response or lead to 
immune dysfunction did not act as confounders during flow cytometry analysis. Patients who would 
not be actively treated were also excluded.  
The exclusion criteria are any of: (1) acute pancreatitis, (2) haematological malignancy, (3) recent 
chemo- therapy (past 2 weeks), (4) myelodysplastic syndromes, (5) known neutropenia, (6) HIV 
infection, (7) viral hepatitis infection, (8) pregnancy, (9) blood transfusion >4units in past week, (10) 
oral corticosteroids for >24hours prior to enrolment, (11) decision not for active therapy/for palliative 
care at admission and (12) inability to consent the patient. 
 
eMethods-1: Description of gating and rationale 
An a priori standard operating gating procedure was developed to identify other leukocyte biomarkers 
using the raw flow cytometry data. This involved: (1) initial strategy, based on pre-existing data, (2) 
expert learning and strategy refinement, to ensure ideal identification of leukocyte subtypes, and (3) 
expert consensus and finalisation of the gating strategy. These stages were undertaken iteratively by 
expert flow cytometrists (at least 2 years of flow cytometry experience) with cycles of testing and re-
testing until a final procedure for each biomarker was agreed. We designed five separate panels.  
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Panel-A 
Marker Fluorophore Clone Rationale/justification for use in the study 
CD14 APC-H7 MΦP9  CD14 and CD15 have been chosen to help isolate monocytes 
and neutrophils. CD24, CD35, CD64 and CD312 have been 
chosen as markers of sepsis. Neutrophil CD64 is increased in 
infections. CD24 has been noted to be up regulated in in-vitro 
models of sepsis and blocking this pathway has been 
suggested to ameliorate sepsis. An increased CD312 (EMR2) 
expression on neutrophils has been liked with SIRS. An 
increase in CD35 expression has been linked to bacterial 
infection as compared to viral infection. 
CD15 FITC  W6D3  
CD24 PerCP-Cy5.5  ML5  
CD35 PE  E11  
CD64 PE-Cy7  10.1  
CD312 AF647 (APC)  2A1 Serotec  
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Panel B 
Marker Fluorophore Clone Rationale/justification for use in the study 
CD3  FITC  SK7  The strategy at looking at myeloid and plasmacytoid dendritic 
cells is based on previous studies and a commercial assay 
developed by BD Biosciences. CD3, CD19 and CD56 have been 
chosen, all on the FITC channel, as lineage selection markers to 
help gate for dendritic cells. CD11c and CD123 have been 
chosen to allow differentiation between dendritic cell subtypes. 
CD14 and CD16 have been chosen to detect monocyte 
subtypes. Low monocyte HLA-DR has been associated with 
poor outcome in sepsis. 
CD11c  PerCP-Cy5.5  S.HCL-3  
CD14  APC-H7  MΦP9  
CD16  PE-Cy7  B73.1  
CD19  FITC  4G7  
CD56  FITC  NCAM16.2  
CD123  PE  9F5  
HLA-DR  APC  G46-6  
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Panel-C 
Marker Fluorophore Clone Rationale/justification for use in the study 
CD9  PE  M-L13  CD11b and CD62L have been chosen to be investigated as 
markers of sepsis. CD11b expression is enhanced in neonatal 
sepsis. CD9, CD15 and CD16 have been chosen to explore 
neutrophil progenitors, as immature neutrophils are associated 
with worse outcomes in sepsis patients. 
CD11b  PE-Cy7  ICRF 44  
CD15  FITC  W6D3  
CD16  APC-H7  3G8  
CD62L  APC  DREG-56  
 
 
 
 
Panel-D 
Marker Fluorophore Clone Rationale/justification for use in the study 
CD4  PerCp-Cy5.5  SK3  CD4 and CD8 have been chosen to differentiate between T-
helper and cytotoxic T cells. CD14 and CD16 have been 
chosen to detect monocyte subtypes. CD274 (PD-L1) and 
CD279 (PD-1) are being assessed as potential markers of 
predicting sepsis, as increased expression is associated with 
worse outcomes in critically ill sepsis cohorts. 
CD8  APC-H7  SK1  
CD14  FITC  MΦP9  
CD16  PE-Cy7  B73.1  
CD274  PE  MIH1  
CD279  APC  MIH4  
 
 
Shankar-Hari M et al. Risk of sepsis using leukocyte cell surface makers 6 
Panel-E 
Marker Fluorophore Clone Rationale/justification for use in the study 
CD3  FITC  SK7  CD3 detects lymphocyte, NK and NKT cell populations. 
CD56 has been chosen to detect NKT cells. CD335 has been 
chosen to detect NK cells. CD16, CD56 and CD57 have been 
chosen to detect NK cell subsets. 
CD16  APC-H7  3G8  
CD56  PerCP-Cy5.5  B159  
CD57  APC  NK-1  
CD284  PE  T901  
CD335  PE-Cy7  p9E2/NKp46  
 
 
Gating procedure 
We evaluated stability of sample acquisition assessment by plotting time versus forward scatter and 
eliminated sections of poor flow. We then excluded cell aggregates using flow height versus area on 
the forward scatter. Further artefacts (debris) were eliminated by creating an “all cells” gate on the 
forward versus side scatter. Bi-exponential scaling was used for displaying and gating of flow 
cytometry data. 
 
Neutrophil biomarkers 
1. Display CD15 vs SSC on the ‘all cells’ gate for granulocytes 
2. Gate tightly on CD15hi for neutrophils 
3. Determine MFI for true neutrophil population for CD14, CD15, CD24, CD35, CD64, and CD312  
 
Monocyte biomarkers 
1. Display CD14 vs CD15 on all cells gate 
2. Gate lymphocytes as CD14lo / CD15lo 
3. Display FSC-A vs SSC-A on all cells gate 
4. Gate for presumed monocytes by light scatter properties 
5. Calculate true monocyte gate as “presumed monocytes” NOT lymphocytes NOT neutrophils 
6. Display CD14 vs CD15 on true monocyte gate 
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7. Plot 3 gates: total monocytes will be the largest rectangular gate, and 2 further gates: CD14hi 
monocytes and CD14lo monocytes 
8. Determine MFI for CD14, CD15, CD24, CD35, CD64, and CD312 markers on each monocyte 
population 
 
Dendritic cells 
1. Display Lin− (FITC-A) histogram on non-neutrophil gate (Note when referring to Lin- (lineage 
negative) we are referring to the CD3negative / CD19negative / CD56 negative population.  
2. Gate for Lin− population using the marker tool - take the upper marker to the base of the Lin+ 
population 
3. Display HLA-DR vs CD14 on the above Lin− subpopulation 
4. Gate HLA-DRpositive / CD14negative sub-population using a square or polygon gate 
5. Display sub-population as CD16 vs SSC 
6. Gate for total dendritic cells (DCs) as CD16negative using a square gate 
7. Report total DCs as % of non-granulocyte cells 
8. Report MFI of HLA-DR on total DCs 
 
Dendritic cell subsets 
1. Display CD123 vs CD11c on the above total DCs 
2. Gate for myeloid dendritic cells as CD11chigh / CD123low 
3. Gate for plasmacytoid dendritic cells as CD11clow / CD123high 
4. Gate for non-specific dendritic cells as CD11clow / CD123low 
5. Report DC subtypes as % of total DCs 
6. Report mDC as % of non-granulocytes 
 
Neutrophil progenitors 
1. Display neutrophil population for CD16 vs CD62L 
2. Gate the following neutrophil sub-types: 
a. CD16hi as mature neutrophils 
b. CD62Lhi / CD16mid (as presumed late immature neutrophils) 
c. CD62Llo / CD16lo (as early immature neutrophils) 
3. Record each gate as percentage of total granulocytes 
 
Natural Killer T cells 
1. Display CD3 vs CD56, on total lymphocytes 
2. Report NKT cells (CD3+/CD56+) as % of total lymphocytes 
 
Natural Killer cells and subsets 
1. Display CD3 vs CD335, on total lymphocytes 
2. Gate NK cells as CD3−/CD335+ 
3. Report total NK cells as % of total lymphocytes 
4. NK subsets 
a. Display CD16 vs CD56 on total NK cells 
b. Gate naïve NK subset as CD56++ / CD16−; report as % of total NK cells 
c. Gate mature NK subset as CD56+ / CD16+; report as % of total NK cells 
d. Cytotoxic NK subset 
i. Display histogram of CD57 on CD56+ / CD16++ mature NK subset (from 
previous step) 
ii. Report CD57high cytotoxic NK subset as % of mature NK cells (i.e. parent 
population) 
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eMethods-2: Reliability and optimisation 
Sample size 
Based on published recommendations5, a sample size of 50 files was selected for the measurement 
of inter-observer agreement, and 13 files were selected for intra-observer agreement. For intra-
observer agreement each expert observer re-analysed a different set of 13 files. For inter-observer 
agreement three different readers analysed the same 50 files. All 47 biomarkers were read from each 
file. For the intra-observer agreement, the files were presented in random order to readers by an 
independent individual.  
 
Statistical testing of reproducibility 
Each panel biomarker was assessed separately for intra- followed by inter-rater reliability. Reliability 
was assessed using intra-class correlation (ICC) coefficients and Bland-Altman plots. These 
measures were generated for both intra- and inter- observer agreement. ICC is expressed on a scale 
from 0 to 1: an ICC of 1.0 is interpreted as no variance between each observer, the ideal situation 
where observers can be considered interchangeable. An ICC cut-off of 0.9 was selected as the 
threshold for selection on the basis of previous literature. ICCs below this were judged to have 
inadequate reliability. 
Analysis of each laboratory marker generated 3 intra-observer ICC coefficient statistics, describing 
the repeatability of reading by each observer. For inter-rater reliability each marker had 1 ICC 
coefficient statistic, describing the repeatability of the gating strategy across the 3 observers. Further 
assessment of each reader and each marker was performed using descriptive summary statistics and 
Bland-Altman statistics as required. Logarithmic transformation of data was carried out for further 
analyses if any data was not normally distributed. Bland-Altman plots were displayed as means vs 
differences, with the mean of differences referred to as bias, and upper and lower limits of 
agreements (U-LoA and L-LoA respectively) also generated. 
 
Interpretation of reliability statistics 
A protocol and rules-based system was created a priori to interpret the results of the reliability study 
(Figure 1). Intra-observer reliability was assessed first; the rationale being that intra-rater reliability 
was essential before any comparison between readers was likely to have clinical utility in discriminant 
analysis. If intra-rater reliability was established, the analysis proceeded to inter-observer reliability 
analysis. We required biomarkers to demonstrate both intra- and inter-rater reliability in order to be 
taken to the cross-cohort comparisons. 
The interpretation strategy was designed to allow re-examination of markers which might potentially 
be falsely excluded due to any single data points which might be outliers. 
 
 
 
 
 
Protocol for reliability assessment 
Intra-observer reliability 
Step 1 
a. Is the intra-observer ICC for all 3 observers is greater than or equal to 0.9? 
b. If yes, the outcome will be classified as having high reliability, and biomarker taken forward to 
the inter-observer interpretation stage 
c. If no, proceed to step 2 
Step 2 
a. Do 2 out of 3 observers have an intra-observer ICC of greater than or equal to 0.9? 
b. If no, outcome classified as having low reliability, and biomarker not be taken forward for 
primary analysis 
c. If yes, proceed to step 3 
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Step 3 
a. Data further analysed with a Bland-Altman plot and summary statistics. Qualitative and 
quantitative assessment of systematic bias, limits of agreement, and note if there are any 
points felt to be outliers. 
b. Expert decision whether biomarker should be re-classified as having high reliability? 
c. If yes, biomarker taken forward to the inter-observer interpretation stage 
d. If no, biomarker not taken forward 
 
Inter-observer reliability data 
Step 1 
a. Is the overall inter-observer ICC greater than or equal to 0.9? 
b. If yes, the biomarker classified as having high reliability.  
c. If no, proceed to step 2. 
Step 2 
a. Was poor agreement caused by a small number of outlier comparisons from one reader?  
b. Was poor agreement attributable due to a single reader with a systematic bias? 
c. Were limits of agreement consistent with acceptable precision? 
d. Based on a-c assessment biomarker classified as having adequate reliability or rejected from 
further evaluation. 
 
Results from statistical assessment 
The results from the intra- and inter-rater reliability studies is shown in etable-2. 
  
Shankar-Hari M et al. Risk of sepsis using leukocyte cell surface makers 10 
eTable-1: Leukocyte biomarkers evaluated  
Leukocyte subset  Biomarker measurement description 
Neutrophil biomarkers 
(N = 12 biomarkers) 
MFI for CD14, CD15, CD24, CD35, CD64, CD312, CD11b, CD274, 
CD279 
CD62L low CD16 low neutrophil subset as proportion of total 
neutrophils 
CD16 high neutrophil subset as proportion of total neutrophils 
CD62L high CD16 mid neutrophil subset as proportion of total 
neutrophils 
Monocyte biomarkers 
(N = 22 biomarkers) 
MFI for CD14, CD15, CD24, CD35, CD64, CD312, CD11b 
MFI for HLA-DR as measured on total monocytes, classical 
monocyte subset, non-classical monocyte subset, and intermediate 
monocyte subset 
MFI for CD274 as measured on total monocytes, classical monocyte 
subset, non-classical monocyte subset, and intermediate monocyte 
subset 
MFI for CD279 as measured on total monocytes, classical monocyte 
subset, non-classical monocyte subset, and intermediate monocyte 
subset 
Classical, intermediate and non-classical monocyte subsets, all 3 as 
proportion of total monocytes 
Dendritic cell biomarkers 
(N = 6 biomarkers) 
MFI for HLA-DR measured on total dendritic cells 
Total dendritic cells, and myeloid dendritic cells, both as proportion 
of non-granulocyte cells 
Myeloid, plasmacytoid, and non-specific dendritic cell subtypes, as 
proportion of total dendritic cells 
Lymphocyte biomarkers 
(N = 2 biomarkers) 
MFI for CD274 and CD279 measured on CD8 lymphocytes 
Natural killer cell 
biomarkers 
(N = 5 biomarkers) 
Natural Killer cells and NKT cells, both measured as proportion of 
total lymphocytes 
Naïve, mature and cytotoxic NK subsets, measured as proportion of 
total Natural Killer cells 
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eTable-2: Table of Intraclass correlation coefficients (ICC) from the intra- and inter-rater 
reliability studies for each of the 47 biomarkers. Biomarkers rejected on intra-rater reliability 
testing are shown in red. Biomarkers rejected on inter-rater reliability testing are shown in 
blue 
 
Marker Inter-observer ICC Intra-observer ICC 
Edinburgh Newcastle London 
Neutrophil CD14 1 1 1 1 
Neutrophil CD15 1 1 1 1 
Neutrophil CD24 1 1 1 1 
Neutrophil CD35 1 1 1 0.9999 
Neutrophil CD64 1 1 1 1 
Neutrophil CD312 1 1 1 0.9995 
Monocyte CD14 0.9998 1 1 0.9993 
Monocyte CD15 0.9998 1 0.9998 0.9997 
Monocyte CD24 0.999 0.9986 0.9996 0.999 
Monocyte CD35 0.9992 0.9997 0.9997 0.9994 
Monocyte CD64 0.9997 0.9998 0.9996 0.9993 
Monocyte CD312 0.9943 0.9998 0.9997 0.9985 
HLA-Dr expression on all dendritic cells (DCs) 0.7785 0.9557 0.9675 0.935 
Myeloid DC as % of parent cell 0.829 0.8373 0.9942 0.7764 
Non-specific DC as % of parent cell 0.864 0.6017 0.9873 0.9364 
Plasmacytoid DC as % of parent cell 0.7611 0.9704 0.9796 0.9434 
Total DC as % of non-granulocyte cells 0.7484 0.967 0.9582 0.9266 
Myeloid DC as % of non-granulocyte cells 0.8208 0.9305 0.9961 0.8775 
HLA-Dr expression on all monocytes 0.9994 0.9996 0.9994 0.9997 
HLA-Dr expression on classical monocytes 0.9989 0.9997 0.9995 0.9997 
HLA-Dr expression on non-classical monocytes 0.9299 0.9762 0.9933 0.9962 
HLA-Dr expression on intermediate monocytes 0.9962 0.9976 0.9976 0.989 
Classical monocytes, as % of all monocytes 0.929 0.9985 0.9938 0.9928 
Non-classical monocytes, as % of all monocytes 0.9744 0.9887 0.9716 0.9907 
Intermediate monocytes, as % of all monocytes 0.959 0.9929 0.9673 0.9678 
Neutrophil CD11b.mfi 0.9999 1 0.9999 0.9999 
Monocyte CD11b.mfi 0.9968 0.9978 0.9991 0.9995 
Neutrophil CD16hi 0.7295 0.9843 0.8097 0.915 
Neutrophil CD62Lhi/CD16mid 0.798 0.9844 0.802 0.9383 
Neutrophil CD62Llow/CD16low 0.9493 0.9962 0.9929 0.9827 
CD274 expression on CD8 lymphocytes 0.812 0.5054 0.9903 0.9771 
CD274 expression on classical monocytes 0.9997 0.9998 0.9999 0.9453 
CD274 expression on non-classical monocytes 0.9855 0.6597 0.997 0.9182 
CD274 expression intermediate monocytes 0.9793 0.9919 0.9963 0.9594 
CD274 expression on neutrophils 0.9998 0.998 1 0.9949 
CD274 expression on all monocyte 0.9997 0.9998 0.9997 0.9997 
CD279 expression on CD8 lymphocytes 0.914 0.9937 0.9682 0.9925 
CD279 expression on classical monocytes 0.9943 0.975 0.9993 0.9874 
CD279 expression on non-classical monocytes 0.1717 -0.1038 0.9924 0.974 
CD279 expression on intermediate monocytes 0.9242 0.9189 0.9908 0.9689 
CD279 expression on neutrophils 0.9978 0.9977 0.9989 0.9966 
CD279 expression on all monocytes 0.9935 0.9703 0.9989 0.9863 
NK measured as % of total lymphocytes 0.9985 0.9998 0.9989 0.9963 
NKT measured as % of total lymphocytes 0.9883 0.9986 0.9958 0.9979 
Cytotoxic NK cells, measured as % of NK cells 0.951 0.9888 0.9602 0.8446 
Mature NK cells, measured as % of NK cells 0.8212 0.9765 0.9882 0.916 
Naïve NK cells, measured as % of NK cells 0.7978 0.9681 0.986 0.9348 
Shankar-Hari M et al. Risk of sepsis using leukocyte cell surface makers 12 
eTable-3: Rationale for Biomarkers selected for discriminant analysis in cross cohort comparison 
 
Biomarker Biological role Cross cohort 
Kruskal Wallis test 
Expert assessment Selection 
Neutrophil 
biomarkers 
    
CD14 LPS receptor with TLR4 P < 0.0001 Values cross cohorts mainly within 0-100 MFI range so limited variability. Cell numbers high. 
Differences mainly between cohort 1 and cohorts 2&3 which had similar values and range. 
Overall values lower in cohort 1.  
NO 
CD15 Carbohydrate adhesion 
module 
P < 0.0001 Values for MFI range widely to maximum >8000. Cell numbers high. Clear cross cohort 
differences: highest cohort 3; lowest cohort 2; intermediate cohort 1.  
YES 
CD24 Cell adhesion 
glycoprotein; mediates 
cell apoptosis. 
Neutrophil expression 
P < 0.001 Values for MFI cross cohort range widely to >50000. Cell numbers high. Clear cross cohort 
differences: highest cohort 1&2 with wide variability; lowest in cohort 1. Potential biological 
significance 
YES 
CD35 Complement receptor 
(type 1).  
P < 0.0001 Values for MFI range widely to maximum >60000. Cell numbers high. Clear cross cohort 
differences: highest cohort 2; lowest cohort 3; intermediate cohort 1. 
YES 
CD64 Fc-gamma receptor 1 P < 0.0001 Values for MFI range widely to maximum >20000. Cell numbers high. Clear cross cohort 
differences: highest cohort 2; lowest cohort 3; intermediate cohort 1. 
YES 
CD312 G-protein coupled 
molecule 
P < 0.0001 Values for MFI range to maximum >3000. Cell numbers high. Clear cross cohort differences: 
highest cohort 2; lowest cohort 1; intermediate cohort 2. 
YES 
CD11b Complement receptor 3 P < 0.0001 Values for MFI range widely to maximum >60000. Cell numbers high. Clear cross cohort 
differences: highest cohort 1; lower and similar in cohorts 2&3. 
YES 
CD62L low CD16 low 
as % total neutrophils 
Exploratory group P < 0.0001 Values for percent mostly <2% with small number of outliers. Percent in small numbers ranged to 
>5%. Cell numbers very low. Cross cohort differences lack potential for discrimination. 
NO 
CD274 PD1 ligand P < 0.0001 Values for MFI range to maximum >1000. Cell numbers high. Clear cross cohort differences: 
highest cohorts 1&2; lowest 3. 
YES 
CD279 PD1 P < 0.0001 Values for MFI range to maximum ≈1000. Cell numbers high. Clear cross cohort differences: wide 
range of values in cohorts 1&2 with lower values than cohort 3. Values consistently high in cohort 
3. 
YES 
Monocyte 
biomarkers 
    
CD14 LPS receptor with TLR4 P = 0.277 No cross cohort differences. Biomarker was mainly selected as monocyte selection marker NO 
Shankar-Hari M et al. Risk of sepsis using leukocyte cell surface makers 13 
CD15 Carbohydrate adhesion 
module 
P = 0.036 Minimal cross cohort differences NO 
CD24 Cell adhesion 
glycoprotein; mediates 
cell apoptosis. 
Neutrophil expression 
P < 0.017 
 
Minimal cross cohort differences. Lacks biological plausibility for monocytes. NO 
CD35 Complement receptor 
(type 1).  
P < 0.0001 Values for MFI range widely to maximum >40000. Cell numbers moderate. Clear cross cohort 
differences: highest cohorts 1&2; lowest cohort 3. 
YES 
CD64 Fc-gamma receptor 1 P < 0.0001 Values for MFI range widely to maximum >100000 (in cohort 1). Cell numbers intermediate. Clear 
cross cohort differences: highest cohorts 1&2; lowest cohort 3. 
YES 
CD312 EMR2 cell surface 
marker on monocytes 
P = 0.009 Values for MFI range to maximum >6000. Cell numbers intermediate. Some cross-cohort 
differences: highest cohort 2; lower in cohorts 1&3. 
YES 
CD11b Complement receptor 3 P < 0.0001 Values for MFI range widely to maximum >80000. Cell numbers intermediate. Some cross cohort 
differences: highest cohorts 1&2; lower cohorts 3. 
YES 
CD274 total 
monocytes 
PD1 ligand - check point 
inhibitors family 
P < 0.0001 Values for MFI range to maximum >1000. Cell numbers intermediate. Some cross cohort 
differences: highest cohorts 1&2; lowest 3. 
YES 
CD279 total 
monocytes 
PD1 – check point 
inhibitors family 
P < 0.0001 Values for MFI range to maximum ≈500. Cell numbers intermediate. Clear cross cohort 
differences: wide range of values in cohorts 1&2 with lower values than cohort 3. Values 
consistently high in cohort 3. 
YES 
HLA-DR total 
monocytes 
Antigen presentation P < 0.0001 Values for MFI range to >30000. Cell numbers high. Clear cross cohort differences with highest 
levels in cohort 3, lowest in cohort 2, and intermediate with wide range in cohort 1. 
YES 
Percent classical 
monocytes 
 P<0.0003 Although differences apparent across the three groups, the cell numbers for non-classical and 
intermediate monocyte groups low. General patterns suggest lower percentages of classical 
monocytes in cohort 2 relative to cohorts 1&3; lower percent non-classical monocytes in cohort 1 
compared to cohorts 2&3; lower percent of intermediate monocytes in cohort 3 compared to 
cohorts 1&2. Likely mathematical linkage and collinearity between these biomarkers, which would 
be problematic in discriminant and multivariable analysis. 
NO 
Percent non-classical 
monocytes 
 P < 0.0001 
 
Percent intermediate 
monocytes 
 P < 0.0001 
 
CD274 on classical 
monocytes 
PD1 ligand - check point 
inhibitors family 
P < 0.0001 Although differences across groups exist, cell numbers small and absolute differences in MFI 
values between groups small. Likely mathematical linkage and collinearity with CD274 on total 
monocytes, which would be problematic in discriminant and multivariable analysis 
NO 
CD274 on 
intermediate 
monocytes 
PD1 ligand - check point 
inhibitors family 
P < 0.0001 
CD279 on classical 
monocytes 
PD1 – check point 
inhibitors family 
P < 0.0001 Although differences across groups exist, cell numbers small and absolute differences in MFI 
values between groups small. Likely mathematical linkage and collinearity with CD274 on total 
monocytes, which would be problematic in discriminant and multivariable analysis 
NO 
CD279 on 
intermediate 
monocytes 
PD1 – check point 
inhibitors family 
P < 0.0001 
HLA-DR on classical 
monocytes 
 P < 0.0001 Patterns all mirror differences across cohorts for HLA-DR on total monocytes. Cell numbers for 
non-classical and intermediate monocytes very low. Likely mathematical linkage and collinearity 
with HLA-DR on total monocytes, which would be problematic in discriminant and multivariable 
analysis 
NO 
HLA-DR on non-
classical monocytes 
 P < 0.0001 
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HLA-DR on 
intermediate 
monocytes 
 P < 0.0001 
     
Lymphocyte 
biomarkers 
    
CD279 on CD8 T cells PD1 – check point 
inhibitors family 
P < 0.0001 Cell numbers intermediate. Some cross cohort differences: highest cohorts 1 and 2.  YES 
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eTable-4: Members of the independent expert review group who reviewed the provisional data from 
reliability, cross cohort comparisons, and discriminant analysis for the primary and secondary 
outcomes. This group recommended the post hoc extreme phenotype analysis to further explore 
differences between patients who subsequently recovered quickly versus progressed to severe 
sepsis. 
 
Name Position, Institution 
Mervyn Singer Professor of Intensive Care Medicine, University 
College, 
London, UK 
Jean-Daniel Chiche Professor of Critical Care Medicine, 
Hospital Cochin,  
Paris, France 
Paul Dark Professor of Critical Care Medicine, 
University of Manchester, 
Manchester, UK 
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eTable-5: Comparison of recent leukocyte biomarker studies using multi-site flow cytometry with standardisation for 
illness trajectory prediction 2-4 
Study 
characteristics 
Current study (EXPRESS) N=259 Guerin E at al 4 N=177 Daix T el al2 N=781 Conway-Morris A et al 3 N=138 
Primary 
objective 
Predict deterioration to develop sepsis 
sepsis-3 sepsis within 24 or 72 hours 
Predict early evolution (deterioration or 
stability/improvement) of sepsis at 48 
hours 
Predict early evolution (deterioration or 
stability/improvement) of sepsis 
Validate6 cellular markers of immune 
dysfunction to stratify risk of secondary 
infection 
Case 
definition at 
sampling 
Patients with suspected infection 
attending ED 
Patients with sepsis, severe sepsis or 
septic shock 
Patients with sepsis, severe sepsis or 
septic shock 
Critically ill patients predicted to remain 
in ICU for >=48 hours 
Sites (N) 4 1 11 4 
Number of 
leukocyte 
biomarkers 
evaluated 
47 leukocyte biomarkers including 
leukocyte subsets (see eTable-1) 
assessed for reliability, discriminant 
value, followed by best subsets logistic 
regression 
24 markers and 23 leukocyte subsets 
CD36; CD2; CD294; CD19; CD16; 
CD45; CD11b; CD16; CD8; CD64; 
CD11c; CD10; CD24; CD34; CD123; 
CD138; CD4; CD38; CD25; CD56; 
CD127; CD3; CD116; HLA-DR 
CD64; CD10; CD3; CD24; CD11b; 
CD16; CD45 
Neutrophil Cd88; Monocyte HLA-DR; 
proportion of regulatory T cell subsets 
Key findings Optimum biomarker combination of 
increased neutrophil CD24 and 
neutrophil CD279, and reduced 
monocyte HLA-DR expression to predict 
subsequent deterioration to sepsis 
Immature granulocytes (CD10dim 
CD16dim) predicted clinical 
deterioration 
Immature granulocytes associated with 
clinical worsening, when associated 
with T cell lymphopenia 
Confirmed our previous findings6 
Comparison 
of key 
findings of 
other studies 
with our 
EXPRESS 
study 
 CD16low subset did not have cross 
cohort discrimination in our EXPRESS 
study 
CD64 MFI had univariate association, 
which disappeared with best-subsets 
logistic regression. Lymphopenia did 
not have cross cohort discrimination; 
CD24 expression in neutrophils was 
associated with clinical deterioration in 
our EXPRESS study 
Different study population; HLA-DR was 
associated with clinical deterioration to 
sepsis in our EXPRESS study 
Biological 
relevance of 
key markers 
reported in 
each study 
CD24 expressed on mature 
granulocytes and B cells; down-
regulated on neutrophils in sepsis, 
induces neutrophil apoptosis which is 
impaired in sepsis. CD279 and HLA-DR 
are markers of associated with sepsis 
related immunosuppression 
consistently reported in literature 
Myeloid derived immature granulocytes 
appear cytotoxic towards T lymphocytes 
CD64 is a Fc gamma receptor 
expressed on leukocytes; consistently 
reported as a diagnostic marker for 
sepsis 
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eFigure-1: Flow diagram showing the decision analysis for assessing intra- and inter-rater 
reliability for the 47 biomarkers, and selecting biomarkers considered reliable for evaluation in 
cross cohort comparisons. This algorithm is replicated as presented in the protocol 
manuscript 1. 
 
 
 
Shankar-Hari M et al. Risk of sepsis using leukocyte cell surface makers 18 
eFigure-2: Extreme phenotype derivation 
 
 
 
The ‘sick’ phenotype was composed of patients from Cohort 1 who: had a confirmed 
diagnosis of infection; had  SOFA score of 2 or more at both 24 hours and at 72 hours; and 
who were still in hospital and still on antibiotics at 72 hours. After these exclusions 61 
patients remained. The clinical characteristics of these patients were then examined, in 
particular the SOFA score components and functional co-morbidity index. Patients in whom 
the SOFA score was primarily due to pre-existing chronic illness were excluded (details of 
these patients are given in appendix 1). The selection of patients for the sick phenotype is 
shown in Figure 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
 
 
  
  
 
 
 
Figure 2. ‘Sick’ phenotype 
 
 
Cohort 1 
272 patients 
239 patients 
165 patients 
139 patients 
61 patients 
Sick phenotype 
52 patients 
Patients without 
confirmed infection 
excluded (33 patients) 
Patients discharged 
within 72 hours 
excluded (74 patients) 
Patients not on 
antibiotics at 72 hours 
excluded (26 patients) 
Patients with SOFA 
<2 at 24 OR at 72 
hours excluded (78 
patients) 
Patients whose SOFA 
was primarily due to 
chronic illness 
excluded (9 patients) 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
    
 
 
  
  
 
 
 
Figure 1. ‘Well’ phenotype 
 
 
 
 
 
 
 
Cohort 1 
272 patients 
99 patients 
82 patients 
80 patients 
59 patients 
Well phenotype 
40 patients 
Patients with ED 
SOFA  score ≥ 2 
excluded (173 
patients) 
Patients with 24 hour 
SOFA score ≥ 2 
excluded (17 patients) 
Patients with 72 hours 
SOFA score ≥ 2 
excluded (2 patients) 
Patients with positive 
microbiology excluded 
(21 patients) 
Patients still on 
antibiotics at 72 hours 
excluded (19 patients) 
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eFIgure-3: Cross cohort comparison of significant markers taken forward for further evaluation 
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eFIgure-3a: Neutrophil markers
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eFIgure-3: Cross cohort comparison of significant markers taken forward for further evaluation 
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eFIgure-3b: monocyte biomarkers and CD279 on CD8-T cells
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eFigure-4: Biomarker profile differences in the well versus sick extreme phenotype 
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